Previous studies have suggested that phospholipid degradation is closely associated with the development of sarcolemmal membrane injury. This study was initiated to characterize the effects of synthetic inhibitors of phospholipase activities using a cultured myocardial cell model in which arachidonic acid is liberated after treatment with the metabolic inhibitor, iodoacetate. Pretreatment with a steroidal diamine (U26,384) blocked the degradation of labeled phosphatidylcholine and the release of arachidonic acid in cultured myocardial cells during ATP depletion. Inhibition of phospholipid degradation by U26,384 prevented the development of sarcolemmal membrane defects and the release of creatine kinase from the cultured myocardial cells during ATP depletion. Pretreatment with U26,384 had no significant effect on the extent of ATP depletion after iodoacetate treatment, which indicates that the activity of this compound could not be simply ascribed to a sparing effect on ATP concentration. These results support the hypothesis that the development of sarcolemmal membrane injury and the associated loss of cell viability are causally related to progressive phospholipid degradation. In addition, these studies indicate that the release of arachidonic acid during ATP depletion is associated with the net loss of the phosphatidylcholine molecule.
Introduction
Alterations in myocardial membrane structure and function are important in the development of myocardial cell injury during ischemia. Although the biochemical mechanisms for these alterations are unknown, previous studies in an ischemic liver model have suggested that changes in the content and composition of membrane phospholipids may play an important role in the transition from reversible to irreversible cell injury (1, 2) .
These studies in ischemic liver may have relevance to the pathogenesis of irreversible injury during myocardial ischemia. Recently, there have been several reports that the onset of irreversible injury in ischemic canine myocardium corre- lates with the accumulation of free fatty acids, including arachidonic acid, a fatty acid normally present entirely in membrane phospholipid (3) (4) (5) (6) . In a cultured myocardial cell model, the progressive release of arachidonate from myocardial membrane phospholipids is closely linked to the development of sarcolemmal membrane defects, electrolyte derangements, including calcium accumulation, and the associated loss ofcell viability during ATP depletion (7) (8) (9) .
Although these previous studies document a temporal correlation between arachidonic acid release and the onset of irreversible cell injury, they do not necessarily indicate a causal relationship between these two events. The availability of agents that would inhibit the release of arachidonic acid from myocardial cells would allow a critical assessment ofthe role of phospholipid degradation in the development of irreversible injury, and might also provide insight into the biochemical mechanisms that are responsible for the liberation of arachidonic acid.
Accordingly, this study was initiated to characterize the effects of potential synthetic inhibitors of myocardial phospholipase activities, and used a cultured myocardial cell model to test compounds that inhibit the activity ofphospholipases in vitro. As a result of examining the effects of several compounds, a steroidal diamine (U26,384)' was selected for detailed analysis (Fig. 1) . In these studies, evidence was obtained that U26,384 blocked the degradation of phosphatidylcholine, the accumulation of corresponding water-soluble choline-containing metabolites, and the release of arachidonic acid in cultured myocardial cells during ATP depletion. In addition, pretreatment with U26,384 prevented the development of sarcolemmal membrane defects and the release of creatine kinase from the cultured myocardial cells during ATP depletion. These results provide the strongest evidence thus far that the development of sarcolemmal membrane injury and the associated loss of cell viability are causally related to increased degradation of membrane phospholipids. In addition, these 1. U26,384 was developed by the Upjohn company, Kalamazoo, MI (personal communication, Dr. S. Bunting, Lipids Research) and has been shown to inhibit porcine pancreatic phospholipase (IC50, 50±5 liM), to prevent collagen-induced platelet aggregation (IC50, 8.2±0.9 ,uM), and to block the release of arachidonic acid metabolites from neutrophils. In these platelet and neutrophil studies, the inhibition of the formation of arachidonic acid metabolites was overcome by the addition of exogenous arachidonic acid, which indicates that the effect of U26,384 was directed at the level of preventing the liberation of arachidonic acid, rather than on the inhibition of the subsequent metabolism of the free arachidonic acid. Thus, the effects of U26,384 on isolated enzyme and cell systems supported the classification of U26,384 as a synthetic phospholipase inhibitor. However, these results do not preclude a concomitant effect of U26,384 on the lipid substrate. studies indicate that the release of arachidonic acid during ATP depletion is not limited to an imbalance in fatty acid deacylation-reacylation of phospholipids, but appears to be associated with the net loss of the phosphatidylcholine molecule.
Methods
Myocardial cell cultures. Neonatal rat myocardial cells were cultured by a modification of previous methods (7) (8) (9) (10) . Whole hearts were isolated from 2-3-d-old rats and minced in a balanced salt solution containing MgSO4 7H20 (0.2 g/liter), NaCl (6.8 g/liter), KCl (0.4 g/ liter), NaH2PO4H20 (1.5 g/liter), glucose (1 g/liter), and Hepes (4.76 g/liter) at pH 7.5. The myocardial cells were dispersed by the addition ofthe balanced salt solution containing 0.06% pancreatin (Gibco Laboratories, Grand Island, NY) and 0.03% collagenase type II (Worthington Biochemical Corp., Freehold, NJ), and then stirred at 37°C. The supernatant was removed and discarded. The cells were incubated with fresh pancreatin-collagenase for 20 min at 37°C, the supernatant was collected, and the cells were isolated by centrifugation in a tabletop centrifuge for 4 min at 1,400 rpm. The cells were resuspended in 2 ml of newborn calf serum (Gibco Laboratories) and kept at 37°C. The digestion steps were repeated four times and the cell suspensions from each digestion were combined and centrifuged at 2,100 rpm for 6 min. The cells were resuspended in MEM (1.8 mM Ca") (Gibco Laboratories) supplemented with 10% horse serum, 5% FCS, and 1% antibiotics (penicillin 10,000 U/ml and streptomycin 10 Analytical techniques. The separation of phospholipids and free arachidonic acid was performed as previously described (1) . Medium and cells were extracted for lipid analysis by the method of Bligh and Dyer (11). To separate the neutral lipids, including free fatty acids, aliquots of the lipid extracts were spotted on silica gel G TLC plates and developed with a solvent system of hexane/diethyl ether/acetic acid (80:20:1.2). The various phospholipid species were separated by TLC using a solvent system ofchloroform/methanol/acetic acid/water (75:45:10:6). The lipid spots were visualized under ultraviolet light after spraying the plate with 0.02% dichlorofluoroscein, then they were scraped directly into scintillation vials, or subsequently eluted for further lipid analyses.
ATP content (7), cellular protein content (12), creatine kinase activity (13) , lipid phosphorus (7), and light and electron microscopy of cell morphology (7) were performed according to previously described methods. Statistical analysis was performed using analysis of variance and Duncan's multiple range test. Differences between groups were considered significant at P < 0.05 (14) .
Results
Effect of U26,384 on arachidonic acid release during ATP depletion. As previously reported (7), treatment of the cultured myocardial cells with iodoacetate resulted in a time-dependent release of arachidonate from membrane phospholipids (Table  I) . After 4 h of iodoacetate treatment, there was a > 16-37% decrease in radiolabeled arachidonate content of phospholipids, including decreases in phosphatidylcholine, phosphatidylethanolamine, and phosphatidylserine plus phosphatidylinositol, as compared with control plates. The decrease in [3H]arachidonate content of phospholipids was accompanied by a corresponding ninefold increase in the release of radiolabeled arachidonic acid as free fatty acid. Pretreatment of the of ATP depletion, rather than on blunting the effects of iodoacetate on myocardial cell ATP content. The morphology of the myocardial cells was examined by light and electron microscopy after treatment with iodoacetate in the presence or absence of the phospholipase inhibitor. We have previously shown that incubation of the cultured myocytes with iodoacetate results in the time-dependent progression of cellular injury (7, 9) . This injury reaction is detectable with both light and electron microscopy. Contraction bands develop as the cells bleb and assume a rounded rather than normal flattened shape. The myofibrillar contractile apparatus is disorganized as well as contracted and there is a loss of the characteristic sarcomere pattern. The mitochondria become spherical in shape and exhibit swollen cristae. In the late stages of injury, amorphous matrix (flocculent) densities are found in the swollen mitochondria and the sarcolemma shows anatomic defects. Pretreatment with U26,384 prevented all of these manifestations of cell injury at 4 h of iodoacetate treatment (Fig. 4) .
Discussion
To further explore the role of phospholipid degradation and arachidonic acid release in the development of irreversible myocardial injury during ATP depletion, we have characterized the effects of a synthetic inhibitor of phospholipase activity. The potential value of such an inhibitor is twofold. First, this inhibitor allowed the direct evaluation of the role of phospholipase activation in the development of myocardial cell injury. Existing phospholipase inhibitors, such as chlorpromazine, although they show some potential for protection in selected models (17) , they have failed to inhibit phospholipid degradation consistently or to prevent the development of irreversible injury during in vivo myocardial ischemia. Second, these prototype agents, or structurally related analogues, may eventually have important value in developing new agents to protect ischemic myocardium during real or threatened myocardial infarction in man. The specific biochemical mechanisms that are responsible for the liberation of free arachidonic acid during myocardial cell injury are unknown. Myocardial cells contain both phospholipase A and phospholipase C activities, which could contribute to the liberation of arachidonic acid from phosphatidylcholine via separate enzymatic pathways (18) (19) (20) . Phospholipase A activities can directly liberate fatty acids from phosphatidylcholine, which would result in the formation of lysophosphatidylcholine. The lysophosphatidylcholine can be reacylated by lysophosphatidylcholine acyltransferase to phosphatidylcholine (21) . In this manner, the liberation of arachidonic acid would not result in the net loss ofthe phosphatidylcholine molecule nor in the gain of free fatty acids. A similar deacylation-reacylation cycle has been demonstrated in many cell types during arachidonic acid release after the stimulation with various agonists (22, 23) . Instead of being reacylated, the lysophosphatidylcholine molecule can be further degraded to glycerophosphorylcholine, which results in the net liberation of two free fatty acids. In addition, initial cleavage by phospholipase C would produce phosphocholine and diacylglycerol (18, 19) . Subsequently, diacylglycerol and monoacylglycerol lipases can liberate fatty acids from the glycerol backbone.
To distinguish between the possible mechanisms of reacylation versus complete degradation, myocardial cells were ra- Taken together, these results indicate that the liberation of arachidonic acid from phosphatidylcholine during myocardial cell injury is coupled to the hydrolysis of the choline head group and to a net depletion ofphosphatidylcholine from myocardial membranes. These results are compatible with two possibilities: (a) a phospholipase A2 or phospholipase C-initiated process followed by further degradation of lysophosphatidylcholine or diacylglycerol, respectively, or (b) a defective reacylation of arachidonic acid and other fatty acyl moieties followed by further degradation of lysophosphatidyl choline and the release of the water-soluble choline head group. Additional studies are needed to further define the role of phospholipase A and C, lysophospholipases, and the lysophosphatidylcholine-acyltransferase activities in the liberation of arachidonic acid from phosphatidylcholine during ATP depletion.
Inhibition of phospholipid degradation and arachidonic acid release prevents the development ofsarcolemmal defects.
Several studies have demonstrated an association between al-terations in phospholipid metabolism and membrane damage during myocardial cell injury (3, (6) (7) (8) (9) 24) . However, these observations do not necessarily indicate a cause and effect relationship. The availability of a synthetic agent that blocks arachidonic acid release during myocardial cell ATP depletion allows a critical evaluation ofthe role ofphospholipid degradation in the development of membrane damage.
This study has demonstrated that U26,384 inhibits the release of [3H]arachidonic acid and the degradation of ['4C]-phosphatidylcholine, and also prevents the development of sarcolemmal defects as assessed by electron microscopy and the release of creatine kinase into the extracellular medium. Using iodoacetate as a metabolic inhibitor, it has been demonstrated that myocardial cells can withstand large decreases in cellular ATP levels without developing sarcolemmal membrane defects. Since the development of these sarcolemmal defects is a hallmark ofirreversible injury (25, 26) , these results provide additional evidence that the release of arachidonic acid is linked to the onset of irreversible injury of cultured myocardial cells during ATP depletion. However, there are several reasons for interpreting the results of the present study with caution. First, myocardial ischemia has diverse effects on myocardial cell metabolism, particularly on the redox state, in addition to the effects on the depletion of high energy phosphates. Second, the stimulus used for ATP depletion in these studies (iodoacetate) may have effects on the structure and function of myocardial cell membranes beyond the depletion of ATP. Third, it is currently unclear if the response of cultured myocardial cells can be extrapolated to the conditions of in vivo ischemia. Attempts to use U26,384 and related analogues to directly assess this relationship in intact heart models have been hampered by the low solubility of the compound in aqueous solutions. The identification of new synthetic inhibitors in this cultured cell model will be required to eventually allow the critical evaluation of the role of phospholipid degradation in the development of irreversible myocardial injury in ischemic myocardium.
